Swedish Orphan Biovitrum AB - Company Profile
Powered by 
All the data and insights you need on Swedish Orphan Biovitrum AB in one report.
$295
- Save hours of research time and resources with
our up-to-date Swedish Orphan Biovitrum AB Strategy Report
- Understand Swedish Orphan Biovitrum AB position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Swedish Orphan Biovitrum AB Catalyst Calendar
Proactively evaluate Swedish Orphan Biovitrum AB’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Swedish Orphan Biovitrum AB Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 01 Jan 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 01 Jan 2020 | Phase III Trial Completion | Odense University Hospital; Swedish Orphan Biovitrum AB | SOBI | hydroxyurea; peginterferon alfa-2a; peginterferon alfa-2b | Oncology | Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia); Essential Thrombocythemia; Myelofibrosis; Polycythemia Vera | Clinical Trial Registry |
| 31 Oct 2019 | Phase IV Trial Initiation | Dova Pharmaceuticals Inc | - | avatrombopag maleate | Gastrointestinal; Hematological Disorders | Liver Diseases; Thrombocytopenia | Regulatory Website |
| 01 Sep 2019 | Phase II/III Trial Initiation | Light Chain Bioscience; Swedish Orphan Biovitrum AB | SOBI | emapalumab | Hematological Disorders | Hemophagocytic Lymphohistiocytosis | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer